Click for best price
AntiParkinson Drugs Market Size, Share 2024
This research report provides a comprehensive analysis of the Anti-Parkinson Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Anti-Parkinson Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Anti-Parkinson Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Anti-Parkinson Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Anti-Parkinson Drugs market presents opportunities for various stakeholders, including Hospital Pharmacy, Retail Pharmacy. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Anti-Parkinson Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Anti-Parkinson Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Anti-Parkinson Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Anti-Parkinson Drugs market.
Market Overview: The report provides a comprehensive overview of the Anti-Parkinson Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Dopaminergic, Dopamine Agonists), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Anti-Parkinson Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Anti-Parkinson Drugs market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Anti-Parkinson Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Anti-Parkinson Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Anti-Parkinson Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Anti-Parkinson Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Anti-Parkinson Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Anti-Parkinson Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Anti-Parkinson Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Dopaminergic
Dopamine Agonists
Enzyme Inhibitors
Others
Market segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Stores
Global Anti-Parkinson Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
AbbVie
Mylan Laboratories
Valeant Pharmaceuticals
Novartis
GlaxoSmithKline
Zambon Pharmaceuticals
Pfizer, Inc.
Hoffmann-La Roche
Merck & Co.
Orion Pharma
UCB
Teva Pharmaceutical Industries Ltd.
Vertical Pharmaceuticals, LLC
ACADIA Pharmaceuticals Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-Parkinson Drugs, market overview.
Chapter 2: Global Anti-Parkinson Drugs market size in revenue.
Chapter 3: Detailed analysis of Anti-Parkinson Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-Parkinson Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Anti-Parkinson Drugs Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
107 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Anti-Parkinson Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-Parkinson Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-Parkinson Drugs Overall Market Size
2.1 Global Anti-Parkinson Drugs Market Size: 2023 VS 2030
2.2 Global Anti-Parkinson Drugs Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Anti-Parkinson Drugs Players in Global Market
3.2 Top Global Anti-Parkinson Drugs Companies Ranked by Revenue
3.3 Global Anti-Parkinson Drugs Revenue by Companies
3.4 Top 3 and Top 5 Anti-Parkinson Drugs Companies in Global Market, by Revenue in 2023
3.5 Global Companies Anti-Parkinson Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Anti-Parkinson Drugs Players in Global Market
3.6.1 List of Global Tier 1 Anti-Parkinson Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Anti-Parkinson Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Anti-Parkinson Drugs Market Size Markets, 2023 & 2030
4.1.2 Dopaminergic
4.1.3 Dopamine Agonists
4.1.4 Enzyme Inhibitors
4.1.5 Others
4.2 By Type - Global Anti-Parkinson Drugs Revenue & Forecasts
4.2.1 By Type - Global Anti-Parkinson Drugs Revenue, 2019-2024
4.2.2 By Type - Global Anti-Parkinson Drugs Revenue, 2025-2030
4.2.3 By Type - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Anti-Parkinson Drugs Market Size, 2023 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Stores
5.2 By Application - Global Anti-Parkinson Drugs Revenue & Forecasts
5.2.1 By Application - Global Anti-Parkinson Drugs Revenue, 2019-2024
5.2.2 By Application - Global Anti-Parkinson Drugs Revenue, 2025-2030
5.2.3 By Application - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Anti-Parkinson Drugs Market Size, 2023 & 2030
6.2 By Region - Global Anti-Parkinson Drugs Revenue & Forecasts
6.2.1 By Region - Global Anti-Parkinson Drugs Revenue, 2019-2024
6.2.2 By Region - Global Anti-Parkinson Drugs Revenue, 2025-2030
6.2.3 By Region - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Anti-Parkinson Drugs Revenue, 2019-2030
6.3.2 US Anti-Parkinson Drugs Market Size, 2019-2030
6.3.3 Canada Anti-Parkinson Drugs Market Size, 2019-2030
6.3.4 Mexico Anti-Parkinson Drugs Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Anti-Parkinson Drugs Revenue, 2019-2030
6.4.2 Germany Anti-Parkinson Drugs Market Size, 2019-2030
6.4.3 France Anti-Parkinson Drugs Market Size, 2019-2030
6.4.4 U.K. Anti-Parkinson Drugs Market Size, 2019-2030
6.4.5 Italy Anti-Parkinson Drugs Market Size, 2019-2030
6.4.6 Russia Anti-Parkinson Drugs Market Size, 2019-2030
6.4.7 Nordic Countries Anti-Parkinson Drugs Market Size, 2019-2030
6.4.8 Benelux Anti-Parkinson Drugs Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Anti-Parkinson Drugs Revenue, 2019-2030
6.5.2 China Anti-Parkinson Drugs Market Size, 2019-2030
6.5.3 Japan Anti-Parkinson Drugs Market Size, 2019-2030
6.5.4 South Korea Anti-Parkinson Drugs Market Size, 2019-2030
6.5.5 Southeast Asia Anti-Parkinson Drugs Market Size, 2019-2030
6.5.6 India Anti-Parkinson Drugs Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Anti-Parkinson Drugs Revenue, 2019-2030
6.6.2 Brazil Anti-Parkinson Drugs Market Size, 2019-2030
6.6.3 Argentina Anti-Parkinson Drugs Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Anti-Parkinson Drugs Revenue, 2019-2030
6.7.2 Turkey Anti-Parkinson Drugs Market Size, 2019-2030
6.7.3 Israel Anti-Parkinson Drugs Market Size, 2019-2030
6.7.4 Saudi Arabia Anti-Parkinson Drugs Market Size, 2019-2030
6.7.5 UAE Anti-Parkinson Drugs Market Size, 2019-2030
7 Anti-Parkinson Drugs Companies Profiles
7.1 AbbVie
7.1.1 AbbVie Company Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Anti-Parkinson Drugs Major Product Offerings
7.1.4 AbbVie Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.1.5 AbbVie Key News & Latest Developments
7.2 Mylan Laboratories
7.2.1 Mylan Laboratories Company Summary
7.2.2 Mylan Laboratories Business Overview
7.2.3 Mylan Laboratories Anti-Parkinson Drugs Major Product Offerings
7.2.4 Mylan Laboratories Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.2.5 Mylan Laboratories Key News & Latest Developments
7.3 Valeant Pharmaceuticals
7.3.1 Valeant Pharmaceuticals Company Summary
7.3.2 Valeant Pharmaceuticals Business Overview
7.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Major Product Offerings
7.3.4 Valeant Pharmaceuticals Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.3.5 Valeant Pharmaceuticals Key News & Latest Developments
7.4 Novartis
7.4.1 Novartis Company Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Anti-Parkinson Drugs Major Product Offerings
7.4.4 Novartis Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.4.5 Novartis Key News & Latest Developments
7.5 GlaxoSmithKline
7.5.1 GlaxoSmithKline Company Summary
7.5.2 GlaxoSmithKline Business Overview
7.5.3 GlaxoSmithKline Anti-Parkinson Drugs Major Product Offerings
7.5.4 GlaxoSmithKline Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.5.5 GlaxoSmithKline Key News & Latest Developments
7.6 Zambon Pharmaceuticals
7.6.1 Zambon Pharmaceuticals Company Summary
7.6.2 Zambon Pharmaceuticals Business Overview
7.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Major Product Offerings
7.6.4 Zambon Pharmaceuticals Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.6.5 Zambon Pharmaceuticals Key News & Latest Developments
7.7 Pfizer, Inc.
7.7.1 Pfizer, Inc. Company Summary
7.7.2 Pfizer, Inc. Business Overview
7.7.3 Pfizer, Inc. Anti-Parkinson Drugs Major Product Offerings
7.7.4 Pfizer, Inc. Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.7.5 Pfizer, Inc. Key News & Latest Developments
7.8 Hoffmann-La Roche
7.8.1 Hoffmann-La Roche Company Summary
7.8.2 Hoffmann-La Roche Business Overview
7.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Major Product Offerings
7.8.4 Hoffmann-La Roche Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.8.5 Hoffmann-La Roche Key News & Latest Developments
7.9 Merck & Co.
7.9.1 Merck & Co. Company Summary
7.9.2 Merck & Co. Business Overview
7.9.3 Merck & Co. Anti-Parkinson Drugs Major Product Offerings
7.9.4 Merck & Co. Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.9.5 Merck & Co. Key News & Latest Developments
7.10 Orion Pharma
7.10.1 Orion Pharma Company Summary
7.10.2 Orion Pharma Business Overview
7.10.3 Orion Pharma Anti-Parkinson Drugs Major Product Offerings
7.10.4 Orion Pharma Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.10.5 Orion Pharma Key News & Latest Developments
7.11 UCB
7.11.1 UCB Company Summary
7.11.2 UCB Business Overview
7.11.3 UCB Anti-Parkinson Drugs Major Product Offerings
7.11.4 UCB Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.11.5 UCB Key News & Latest Developments
7.12 Teva Pharmaceutical Industries Ltd.
7.12.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Major Product Offerings
7.12.4 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.12.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
7.13 Vertical Pharmaceuticals, LLC
7.13.1 Vertical Pharmaceuticals, LLC Company Summary
7.13.2 Vertical Pharmaceuticals, LLC Business Overview
7.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Major Product Offerings
7.13.4 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.13.5 Vertical Pharmaceuticals, LLC Key News & Latest Developments
7.14 ACADIA Pharmaceuticals Inc.
7.14.1 ACADIA Pharmaceuticals Inc. Company Summary
7.14.2 ACADIA Pharmaceuticals Inc. Business Overview
7.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Major Product Offerings
7.14.4 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Revenue in Global Market (2019-2024)
7.14.5 ACADIA Pharmaceuticals Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Anti-Parkinson Drugs Market Opportunities & Trends in Global Market
Table 2. Anti-Parkinson Drugs Market Drivers in Global Market
Table 3. Anti-Parkinson Drugs Market Restraints in Global Market
Table 4. Key Players of Anti-Parkinson Drugs in Global Market
Table 5. Top Anti-Parkinson Drugs Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Anti-Parkinson Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Anti-Parkinson Drugs Revenue Share by Companies, 2019-2024
Table 8. Global Companies Anti-Parkinson Drugs Product Type
Table 9. List of Global Tier 1 Anti-Parkinson Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-Parkinson Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Anti-Parkinson Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Anti-Parkinson Drugs Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Anti-Parkinson Drugs Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Anti-Parkinson Drugs Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Anti-Parkinson Drugs Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Anti-Parkinson Drugs Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Anti-Parkinson Drugs Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Anti-Parkinson Drugs Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Anti-Parkinson Drugs Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Anti-Parkinson Drugs Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Anti-Parkinson Drugs Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Anti-Parkinson Drugs Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Anti-Parkinson Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Anti-Parkinson Drugs Revenue, (US$, Mn), 2025-2030
Table 30. AbbVie Company Summary
Table 31. AbbVie Anti-Parkinson Drugs Product Offerings
Table 32. AbbVie Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 33. AbbVie Key News & Latest Developments
Table 34. Mylan Laboratories Company Summary
Table 35. Mylan Laboratories Anti-Parkinson Drugs Product Offerings
Table 36. Mylan Laboratories Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 37. Mylan Laboratories Key News & Latest Developments
Table 38. Valeant Pharmaceuticals Company Summary
Table 39. Valeant Pharmaceuticals Anti-Parkinson Drugs Product Offerings
Table 40. Valeant Pharmaceuticals Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 41. Valeant Pharmaceuticals Key News & Latest Developments
Table 42. Novartis Company Summary
Table 43. Novartis Anti-Parkinson Drugs Product Offerings
Table 44. Novartis Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 45. Novartis Key News & Latest Developments
Table 46. GlaxoSmithKline Company Summary
Table 47. GlaxoSmithKline Anti-Parkinson Drugs Product Offerings
Table 48. GlaxoSmithKline Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 49. GlaxoSmithKline Key News & Latest Developments
Table 50. Zambon Pharmaceuticals Company Summary
Table 51. Zambon Pharmaceuticals Anti-Parkinson Drugs Product Offerings
Table 52. Zambon Pharmaceuticals Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 53. Zambon Pharmaceuticals Key News & Latest Developments
Table 54. Pfizer, Inc. Company Summary
Table 55. Pfizer, Inc. Anti-Parkinson Drugs Product Offerings
Table 56. Pfizer, Inc. Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 57. Pfizer, Inc. Key News & Latest Developments
Table 58. Hoffmann-La Roche Company Summary
Table 59. Hoffmann-La Roche Anti-Parkinson Drugs Product Offerings
Table 60. Hoffmann-La Roche Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 61. Hoffmann-La Roche Key News & Latest Developments
Table 62. Merck & Co. Company Summary
Table 63. Merck & Co. Anti-Parkinson Drugs Product Offerings
Table 64. Merck & Co. Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 65. Merck & Co. Key News & Latest Developments
Table 66. Orion Pharma Company Summary
Table 67. Orion Pharma Anti-Parkinson Drugs Product Offerings
Table 68. Orion Pharma Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 69. Orion Pharma Key News & Latest Developments
Table 70. UCB Company Summary
Table 71. UCB Anti-Parkinson Drugs Product Offerings
Table 72. UCB Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 73. UCB Key News & Latest Developments
Table 74. Teva Pharmaceutical Industries Ltd. Company Summary
Table 75. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product Offerings
Table 76. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 77. Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
Table 78. Vertical Pharmaceuticals, LLC Company Summary
Table 79. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product Offerings
Table 80. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 81. Vertical Pharmaceuticals, LLC Key News & Latest Developments
Table 82. ACADIA Pharmaceuticals Inc. Company Summary
Table 83. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product Offerings
Table 84. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Revenue (US$, Mn) & (2019-2024)
Table 85. ACADIA Pharmaceuticals Inc. Key News & Latest Developments
List of Figures
Figure 1. Anti-Parkinson Drugs Segment by Type in 2023
Figure 2. Anti-Parkinson Drugs Segment by Application in 2023
Figure 3. Global Anti-Parkinson Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Anti-Parkinson Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Anti-Parkinson Drugs Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2023
Figure 8. By Type - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 9. By Application - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 10. By Type - Global Anti-Parkinson Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 12. By Application - Global Anti-Parkinson Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 14. By Region - Global Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 15. By Country - North America Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 16. US Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 20. Germany Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 21. France Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 28. China Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 32. India Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 34. Brazil Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Anti-Parkinson Drugs Revenue Market Share, 2019-2030
Figure 37. Turkey Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Anti-Parkinson Drugs Revenue, (US$, Mn), 2019-2030
Figure 41. AbbVie Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Mylan Laboratories Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Valeant Pharmaceuticals Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Novartis Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. GlaxoSmithKline Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Zambon Pharmaceuticals Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Pfizer, Inc. Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Hoffmann-La Roche Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Merck & Co. Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Orion Pharma Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. UCB Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
